Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology

Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is primarily engaged in the development of its pipeline asset AUR200, a differentiated, potential next generation therapy for autoimmune diseases that targets both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand). The Company contracted with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for the development and commercialization of LUPKYNIS in the Otsuka Territories. It sells LUPKYNIS (voclosporin) primarily to specialty pharmacies and a specialty distributor and directly to its ex-U.S. partner, Otsuka.

NDAQ:AUPH - Post by User

Aurinia Pharmaceuticals Inc

Bullboard Posts

Comment by Moneyday0on Aug 25, 2016 7:10am

117 Views

Post# 25174951

RE:Aurinia Material Change Report Aug 22 2016: SEC filing

thanks Allison.... Exactly what was told by those in the know and now in print. There is NO way this is NOT gonna be accepted. The most important point to get right now is the phase III structure covering the data points needed for meeting or exceeding. These guys/gals are on the ball so do not see anything slipping behind the cracks. Very positive for LN patients and those accumulating AUPH... AUP shares.

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload